Investor Corriente Advisors, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Corriente Advisors, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2022-02-14 13G/A CUE / Cue Biopharma, Inc. 1,915,219 0
2022-02-14 13G/A TFFP / TFF Pharmaceuticals, Inc. 1,350,000 0
2022-02-14 13G/A CRDF / Cardiff Oncology, Inc. 2,000,000 0
2021-02-16 13G CRDF / Cardiff Oncology, Inc. 2,000,000
2021-02-16 13G TFFP / TFF Pharmaceuticals, Inc. 1,350,000
2021-02-16 13G CUE / Cue Biopharma, Inc. 1,915,219
2021-02-16 13G/A ATXS / Astria Therapeutics, Inc. 804,584 0
2021-02-16 13G/A NLS / Nautilus Inc 1,813,822 0
2020-02-10 13G/A ATXS / Astria Therapeutics, Inc. 603,129 804,584
2020-01-23 13G NLS / Nautilus Inc 1,813,822
2019-11-26 13G/A MAXR / Maxar Technologies Inc 3,015,000 2,920,750
2019-11-20 13G MAXR / Maxar Technologies Inc 3,015,000
2019-02-13 13G/A ATXS / Astria Therapeutics, Inc. 1,692,899 603,129
2018-02-23 13G ATXS / Astria Therapeutics, Inc. 1,692,899